Last reviewed · How we verify
NCT03509597: CORTEX-SP
Brain Image Markers Associated With Cognitive Training and Aerobic Exercise in Schizophrenia
NA trial testing Aerobic Exercise in Schizophrenia in 150 participants. Status unknown.
31 December 2019
Quick facts
| Lead sponsor | Red Salud Mental Araba |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 1 March 2017 |
| Primary completion | 31 December 2019 |
| Estimated completion | 1 June 2020 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Aerobic Exercise — full drug profile →
- Cognitive Training
- Treatment as usual
- Occupational Activities
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
Sponsor
Red Salud Mental Araba
Who can join
Adults 18 to 65, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the brain correlates of Cognitive Training and Aerobic Exercise in schizophrenia. A third of participants will receive Cognitive Training plus Standard Care for schizophrenia. Another third of participants will receive Aerobic Exercise Training plus Standard Care for schizophrenia. A control group will of participants will receive Standard Care plus Occupational Activities for the same duration and frequency as the experimental groups.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cognitive, creative, functional, and clinical symptom improvements in schizophrenia after an integrative cognitive remediation program: a randomized controlled trial.
Sampedro A, Peña J, Sánchez P, Ibarretxe-Bilbao N, et al · · 2021 · cited 12× · PMID 34711835 · DOI 10.1038/s41537-021-00181-0 -
Mediating role of cognition and social cognition on creativity among patients with schizophrenia and healthy controls: Revisiting the Shared Vulnerability Model.
Sampedro A, Peña J, Ibarretxe-Bilbao N, Sánchez P, et al · · 2020 · cited 9× · PMID 31707749 · DOI 10.1111/pcn.12954 -
Clinical, physical, physiological, and cardiovascular risk patterns of adults with schizophrenia: CORTEX-SP study: Characterization of adults with schizophrenia.
Tous-Espelosin M, de Azua SR, Iriarte-Yoller N, MartínezAguirre-Betolaza A, et al · · 2021 · cited 6× · PMID 33246589 · DOI 10.1016/j.psychres.2020.113580 -
Brain White Matter Correlates of Creativity in Schizophrenia: A Diffusion Tensor Imaging Study.
Sampedro A, Peña J, Ibarretxe-Bilbao N, Cabrera-Zubizarreta A, et al · · 2020 · cited 3× · PMID 32655352 · DOI 10.3389/fnins.2020.00572 -
The impact of creativity on functional outcome in schizophrenia: a mediational model.
Sampedro A, Peña J, Sánchez P, Ibarretxe-Bilbao N, et al · · 2021 · cited 2× · PMID 33637749 · DOI 10.1038/s41537-021-00144-5 -
Differential Responsiveness to Exercise and Cognitive Remediation in Physical Health in People With Schizophrenia: Results From the CORTEX-SP Study.
Tous-Espelosin M, Iriarte-Yoller N, Sampedro A, Lasa-Sagaseta I, et al · · 2026 · PMID 42141376 · DOI 10.1002/ejsc.70182 -
Theory-of-mind improvement in schizophrenia after integrative cognitive remediation: which patients benefit more?
Sampedro A, Peña J, Sánchez P, Ibarretxe-Bilbao N, et al · · 2025 · PMID 40735250 · DOI 10.1016/j.scog.2025.100380 -
As We Were and As We Should Be, Combined Exercise Training in Adults With Schizophrenia: CORTEX-SP Study Part II.
Tous-Espelosin M, Pavon C, Elizagarate E, Sampedro A, et al · · 2024 · PMID 39054763 · DOI 10.1111/sms.14707
Verify or expand the search:
- PubMed search for NCT03509597
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Aerobic Exercise
Trials testing the same drug.
- NCT07517224 — Assessing the Effect of an Aerobic Exercise Program on Vascular Function in Women With Non-Metastatic Breast Cancer · NA · not yet recruiting
- NCT07444333 — Cardiac Output and Fatigue in Friedreich's Ataxia · NA · not yet recruiting
- NCT07182006 — Exercise as Medicine for Pediatric Chronic Pain · NA · not yet recruiting
- NCT07404319 — Effectiveness of Exercise Alone and tDCS+Exercise on Cognitive Function Improvement in Patients With Treatment Resistant · NA · not yet recruiting
- NCT07302204 — Efficacy of Aerobic Exercise Versus Therapeutic Exercises on Exercise-induced Hypoalgesia in Knee Osteoarthritis · NA · recruiting
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03509597 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Red Salud Mental Araba
- Last refreshed: 30 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03509597.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing